 BOSTON--BUSINESS WIRE--MorphoSys AG FSE: MOR; NASDAQ: MOR announced that new data on pelabresib and tafasitamab, marketed in the U.S. as Monjuvi and in Europe as Minjuvi, will be presented during the 2022 American Society of Clinical Oncology Annual Meeting ASCO 2022 in Chicago from June 3 7, 2022 and the 2022 European Hematology Association Hybrid Congress EHA 2022 in Vienna, Austria, from June 9 12, 2022. The data presented at this years EHA and ASCO congresses showcase the br 